Posts by Heather Hare

HD Insights Volume 16 (PDF)

To read a non-PDF version of HD Insights Vol. 16, click here.

2016: Advances and Challenges in HD Therapeutic Development

By: Meredith A. Achey, BM The year 2016 brought a number of notable developments in HD research and therapeutic development....

Brief report: Pfizer Amaryllis trial ends: negative results lead to termination of extension study

By: Molly J. Elson, BA Pfizer’s Phase 2 trial of PF-02545920, a PDE-10 inhibitor, failed to find the efficacy for...

Highly Cited HD Research

In this edition of HD Insights, we take a look at impactful HD research articles of 2015. We searched Thomson...

Research Round-Up

Research Round-Up

By: Lise Munsie, PhD In pharma… The well-tolerated, FDA-approved drug metformin is an antidiabetic drug that mimics caloric restriction. Jin...

MEET THE COMPANY: uniQure

VITAL SIGNS NAME: uniQure STOCK SYMBOL: QURE    SHARE PRICE AS OF 2/17/17: $6.31 52-WEEEK RANGE AS OF 2/17/17: $5.25-$16.40...

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

VITAL SIGNS NAME: Pavlina Konstantinova, MSc, PhD TITLE: Director of Emerging Technologies and Huntington Disease Program Leader, uniQure EDUCATION: MSc,...

MEET THE COMPOUND: AMT-130

MEET THE COMPOUND: AMT-130

By: Meredith A. Achey, BM MANUFACTURER: uniQure COMPOUND: Artificial micro RNA targeting human huntingtin, carried by an adeno-associated virus 5...

Highlights from the Journal of HD

Assistive technology for cognition in HD By: Marleen R. van Walsem, MSc, Emilie I. Howe, MSc and Jan C. Frich,...

Thank you to Teva Pharmaceuticals

HD Insights thanks Teva for its ongoing support Teva CNS is committed to continued research and development of its product portfolio...

1 2 3 4 5 13